Neutrophils: can they predict immunotherapy outcome?
The immune system has many ways of regulating the strength of immune responses such as checkpoint proteins which have an inhibitory role on T cell function. Inhibiting these checkpoint proteins represents an immunotherapy strategy designed to elicit anti-tumour responses. However, this type of immunotherapy exhibits limited clinical success with no clear evidence of the underlying etiology. Funded by the ERC, the BioFlow project capitalises on the discovery of a subpopulation of neutrophils as a biomarker for immune checkpoint inhibitor therapy. With these cells being present in responsive tumours, they offer a powerful tool for predicting response to therapy and also improve the design of future immunotherapy strategies.
Fields of science
- HORIZON.1.1 - European Research Council (ERC) Main Programme